Bruker (NASDAQ:BRKR) Reaches New 52-Week Low - Time to Sell?

Key Points

• Bruker Corporation's stock (NASDAQ:BRKR) hit a new 52-week low, trading as low as $28.53 before closing at $29.63, down from a prior close of $33.23.
• Analysts have recently downgraded their price targets for Bruker, with Barclays reducing theirs from $46.00 to $43.00 and Wells Fargo lowering theirs from $60.00 to $50.00, while the consensus rating remains a "Hold" with an average target of $51.30.
• The company reported earnings of $0.32 EPS for the last quarter, missing estimates by $0.01, and its revenue decreased by 0.4% year-over-year to $797.40 million.

Bruker Corporation (NASDAQ:BRKR - Get Free Report)'s stock price reached a new 52-week low during trading on Wednesday . The stock traded as low as $28.53 and last traded at $29.63, with a volume of 1176378 shares traded. The stock had previously closed at $33.23.

Analyst Upgrades and Downgrades

Several research analysts recently commented on BRKR shares. Barclays cut their price target on Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Monday, August 4th. Jefferies Financial Group set a $60.00 price objective on Bruker and gave the company a "buy" rating in a research note on Monday, August 4th. Wells Fargo & Company cut their price objective on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 5th. Bank of America cut their price objective on Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Finally, The Goldman Sachs Group cut their price objective on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Five research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Bruker has a consensus rating of "Hold" and an average price target of $51.30.

Bruker Trading Down 10.3%

The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $4.52 billion, a price-to-earnings ratio of 57.55, a PEG ratio of 2.79 and a beta of 1.21. The firm has a 50-day moving average of $37.82 and a 200 day moving average of $40.03.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. During the same quarter in the prior year, the business earned $0.52 earnings per share. The firm's revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, equities analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker's dividend payout ratio (DPR) is presently 38.46%.

Insider Buying and Selling at Bruker

In other news, CEO Frank H. Laukien bought 2,608 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was acquired at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the purchase, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. This represents a 0.01% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 27.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bruker

Several large investors have recently modified their holdings of the stock. Orbis Allan Gray Ltd bought a new stake in shares of Bruker during the 2nd quarter worth $192,735,000. London Co. of Virginia boosted its stake in shares of Bruker by 78.4% during the 4th quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock worth $245,820,000 after acquiring an additional 1,843,294 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock worth $137,065,000 after acquiring an additional 1,850,215 shares in the last quarter. Sculptor Capital LP boosted its stake in shares of Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company's stock worth $126,682,000 after acquiring an additional 476,363 shares in the last quarter. Finally, Brown Advisory Inc. boosted its stake in shares of Bruker by 13.9% during the 2nd quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company's stock worth $113,142,000 after acquiring an additional 336,026 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.